Burns Pipeline 2026: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Burns pipeline constitutes 12+ key companies continuously working towards developing 12+ Burns treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Burns Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Burns Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Burns Market.

Some of the key takeaways from the Burns Pipeline Report: https://www.delveinsight.com/sample-request/burns-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Burns treatment therapies with a considerable amount of success over the years.
• Burns companies working in the treatment market are NeoMatrix Therapeutics, Inc., Topadur, Pharmaxis Ltd, Skingenix, Inc, CUTISS AG, and others, are developing therapies for the Burns treatment
• Emerging Burns therapies in the different phases of clinical trials are- NMT-cNP8, TOP-N44, PXS-6302, NMT- cP12, MW-III, DenovoSkinTM, and others are expected to have a significant impact on the Burns market in the coming years.
• In May 2026, Phase IIIa Clinical Trial Initiation: B&K Corporation has dosed the first patient in its pivotal Phase IIIa study of Pro-101-1 (rhPDGF-BB gel) for deep second-degree burns. The trial aims to assess the therapy's safety and effectiveness while generating data to support future regulatory approval efforts.
• In May 2026, Positive Burn Wound Clinical Data: Findings from a multicenter randomized controlled study demonstrated that PermeaDerm, a biosynthetic wound matrix, promoted faster healing in patients with partial-thickness burns and exhibited a strong safety profile when compared with porcine acellular dermal matrix treatment.
• In March 2026, Vasomune Therapeutics, Inc. announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application for the development of Pegevongitide (AV-001) for use in the acute resuscitation of patients with severe burns. Pegevongitide is an injectable Tie2 agonist designed to reduce vascular leakage and is also under investigation for the prevention and treatment of acute respiratory distress syndrome.
• In January 2026, Burn Care Technology Updates: At the 2026 Boswick Burn & Wound Symposium, AVITA Medical unveiled new clinical findings for RECELL®, PermeaDerm®, and CohealyxTM, demonstrating their potential to enhance wound healing, optimize wound bed preparation, and minimize complications in patients with burn injuries.

Burns Overview
Burns are injuries to the skin or other tissues caused by heat, radiation, electricity, chemicals, or friction. They vary in severity from minor to life-threatening and can result in damage to the skin, underlying tissues, and even organs. Burns are classified based on their depth and extent, commonly categorized as first-degree, second-degree, third-degree, and fourth-degree burns.

Get a Free Sample PDF Report to know more about Burns Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/burns-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Burns Drugs Under Different Phases of Clinical Development Include:
• NMT-cNP8: NeoMatrix Therapeutics, Inc.
• TOP-N44: Topadur
• PXS-6302: Pharmaxis Ltd
• NMT- cP12: NeoMatrix Therapeutics, Inc
• MW-III: Skingenix, Inc
• DenovoSkinTM: CUTISS AG

Burns Route of Administration
Burns pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Burns Molecule Type
Burns Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Burns Pipeline Therapeutics Assessment
• Burns Assessment by Product Type
• Burns By Stage and Product Type
• Burns Assessment by Route of Administration
• Burns By Stage and Route of Administration
• Burns Assessment by Molecule Type
• Burns by Stage and Molecule Type

DelveInsight's Burns Report covers around products under different phases of clinical development like development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Burns product details are provided in the report. Download the Burns pipeline report to learn more about the emerging Burns therapies
https://www.delveinsight.com/sample-request/burns-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Burns Therapeutics Market include:
Key companies developing therapies for Burns are - Mallinckrodt Pharmaceuticals, Avita Medical, Vericel Corporation, KeraNetics, Integra LifeSciences Corporation, PolyNovo, MediWound Germany GmbH, Kaken Pharmaceutical Co., Ltd., Kerecis, Medline Industries, Anika Therapeutics, Inc., ACell, Inc., Amryt Pharma, CUTISS AG, Skingenix, RenovaCare, and others.

Burns Pipeline Analysis:
The Burns pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Burns with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Burns Treatment.
• Burns key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Burns Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Burns market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Burns drugs and therapies
https://www.delveinsight.com/sample-request/burns-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Burns Pipeline Market Drivers
• Rising incidence of burns, high demand of Skin grafts, growing awareness of available treatment options are some of the important factors that are fueling the Burns Market.

Burns Pipeline Market Barriers
• However, stringent regulatory approval, high cost of treatment and other factors are creating obstacles in the Burns Market growth.

Scope of Burns Pipeline Drug Insight
• Coverage: Global
• Key Burns Companies: NeoMatrix Therapeutics, Inc., Topadur, Pharmaxis Ltd, Skingenix, Inc, CUTISS AG, and others
• Key Burns Therapies: NMT-cNP8, TOP-N44, PXS-6302, NMT- cP12, MW-III, DenovoSkinTM, and others
• Burns Therapeutic Assessment: Burns current marketed and Burns emerging therapies
• Burns Market Dynamics: Burns market drivers and Burns market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.